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Abstract
Objective. The objectives of the study were to deter-
mine the absolute bioavailability of fentanyl from
fentanyl buccal soluble ﬁlm, estimate the percent-
age of a fentanyl dose absorbed through the buccal
mucosa, and compare the bioavailability of equiva-
lent doses administered either as single or multiple
dose units.
Design. Open-label, randomized, four-period, Latin-
square crossover pharmacokinetic study.
Setting. Inpatient phase 1 unit.
Patients. Twelve healthy volunteers.
Interventions. Injectable fentanyl citrate (200 mg)
administered by intravenous infusion, injectable
fentanyl citrate (800 mg/16 mL) administered orally,
and fentanyl buccal soluble ﬁlm (800 mg) adminis-
tered as a single ﬁlm and as four separate 200 mg
ﬁlms simultaneously.
Outcome Measures. Plasma concentrations after
fentanyl dosing; pharmacokinetic parameters.
Results. The two buccal ﬁlm treatments were
bioequivalent and both had an absolute bioavailabil-
ity of 71%. The percentage of an administered dose
absorbed through the buccal mucosa was calcu-
lated to be 51%.
Conclusions. Fentanyl buccal soluble ﬁlm effec-
tively delivers a high percentage of the administered
fentanyl dose and nearly identical plasma proﬁles
are obtained when equivalent doses are delivered
by single or multiple dosage units.
Key Words. Breakthrough Pain; Buccal Absorption;
Buccal Soluble Film; Drug Absorption; Fentanyl;
Pharmacokinetics
Introduction
Breakthrough pain has been estimated to occur in
approximately 65% of patients with cancer whose pain is
signiﬁcant enough to require opioid analgesics [1]. Man-
agement of breakthrough pain in patients with cancer is a
challenge because onset of breakthrough pain is fre-
quently unpredictable, and episodes vary in both intensity
and duration [2]. Breakthrough pain episodes can be
associated with the end of a dosing interval in patients
with inadequate baseline analgesia, may be associated
with a precipitating event, or may be spontaneous. Epi-
sodes can reach maximal intensity within 3–5 minutes and
occur with a mean frequency of four to seven times daily
[3,4]. Immediate-release oral opioids are frequently used
for the treatment of breakthrough pain, but analgesia may
be delayed within the required therapeutic time frame [2].
The ideal drug for breakthrough pain would produce anal-
gesia in a time frame temporal to the pain episode.
However, this is only achievable with patient-controlled
intravenous analgesia [2]. Alternative routes of administra-
tion differ signiﬁcantly from this ideal in speed of onset,
consistency of effect, and patient convenience. The oral
route is commonly selected for convenience, but analge-
sia may be delayed due to the time required to reach
intestinal absorption sites as well as by delays in gas-
trointestinal motility associated with a background opioid,
or reduced by ﬁrst-pass metabolism. Additionally, oral
delivery of analgesics can be problematic for patients who
have difﬁculty swallowing, are nauseated, or have other
gastrointestinal conditions.
Alternative dosage forms that provide acute relief of
breakthrough pain may be beneﬁcial for appropriate
patients.
Buccal administration can deliver lipophilic opioids rapidly
to the systemic circulation through the buccal mucosa,
limiting gastrointestinal motility and ﬁrst-pass metabolism
[5]. Two forms of fentanyl citrate have been approved in
the United States for the treatment of breakthrough pain in
patients with cancer including an oral transmucosal fen-
tanyl citrate (OTFC) lozenge (Actiq®, Cephalon, Inc.,
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1017Frazer, PA) and a fentanyl effervescent buccal tablet (FBT)
(US: Fentora®, Europe: Effentora®, Cephalon, Inc.; Frazer)
[6]. A relatively wide range of variability in plasma concen-
trations has been reported with the OTFC lozenge, likely
because the fraction of the dose that is swallowed may
vary from dose to dose depending upon how exactly the
device is applied at each occasion. With FBT [7], the
dosing range is limited by nonlinear pharmacokinetics
above 800 mg [8]. Further, there are differences in phar-
macokinetics between multiple units of a lower strength
(4 ¥ 100 mg) and a single higher strength (400 mg) that
authors attributed to differences in the absorptive surface
area [9].
A mucoadhesive, buccal-soluble ﬁlm (Meda Pharmaceu-
ticals, Inc., Somerset, NJ) has also been approved in the
United States using the BioErodible MucoAdhesive
(BEMA™, BioDelivery Sciences, Inc., Raleigh, NC) delivery
technology. Once applied to the oral mucosa, the fentanyl
buccal soluble ﬁlm (FBSF) (US: Onsolis®, Meda Pharma-
ceuticals Inc.) adheres to the mucosa in seconds. Fenta-
nyl is contained in the mucoadhesive layer, and a second
inactive layer separates the fentanyl-containing layer from
the saliva and limits the amount of fentanyl that is swal-
lowed. Each ﬁlm is composed of water-soluble polymers
that completely dissolve so there is no residual product to
be removed, and there is a direct proportional relationship
between the surface area of the ﬁlm and the administered
dose.
The objectives of this open-label, randomized, single-
dose, crossover pharmacokinetic study were to determine
the absolute bioavailability of fentanyl from this advanced
transmucosal delivery system, estimate the percentage of
a fentanyl dose that is absorbed through the buccal
mucosa, and compare the bioavailability of equivalent
doses administered either as single or multiple dose units.
Methods
This was an open-label, randomized, four-period, Latin-
square crossover study. The study protocol was approved
by a regional institutional review board, and the study was
conducted in accord with the principles of the Declaration
of Helsinki and the US Code of Federal Regulations (Title
21, Part 50). All subjects read and signed an approved
informed consent form during screening.
Participants
Subjects eligible for inclusion in the study were healthy
adult male and nonpregnant, nonlactating female volun-
teers aged 18–45 years, weighing 60–100 kg, and within
15% of their ideal body weight based on Metropolitan Life
tables for height and weight. Premenopausal women were
required to use an acceptable method of birth control and
to have a negative urine test for b-human chorionic gona-
dotropin. Consumption of alcoholic beverages, caffeine-
or xanthine-containing beverages, or foods or beverages
containing grapefruit was prohibited from 48 hours prior to
the ﬁrst dose of study medication until discharge from the
study. Use of tobacco or nicotine-containing products
within 30 days of the ﬁrst dose of study medication was
also not allowed.
Subjects were excluded if they had participated in an
investigational drug study within the previous 30 days; had
taken any nutritional supplement or any prescription or
nonprescription medication (except acetaminophen or
oral contraceptives) within 72 hours of the ﬁrst dose of
study medication; or had a positive drug screen for
amphetamines, barbiturates, benzodiazepines, cannab-
inoids, cocaine or opiates, or a positive ethanol breath
test. A history of a serious medical condition, including
glaucoma or a seizure disorder, and allergy or intolerance
to narcotics were also grounds for exclusion.
Trial Design and Procedures
The subjects were assessed at a screening visit and con-
ﬁned to a phase 1 unit throughout the 12-day treatment
period. The Latin-square crossover study design was
used to minimize variability by ensuring each subject
received a single dose for each treatment each period.
Each subject received the following four study treatments
on days 1, 4, 7, and 10: injectable fentanyl citrate 200 mg
administered via an intravenous infusion pump over 5
minutes; injectable fentanyl citrate 800 mg/16 mL admin-
istered orally via a 20 mL oral syringe followed by 90 mL of
water; fentanyl 800 mg as a single ﬁlm applied to the
buccal mucosa; and fentanyl 800 mg administered as four
separate 200 mg ﬁlms applied to the buccal mucosa within
a 2-minute period. The 800 mg ﬁlm provided a surface
area that is four times larger than that of the 200 mg one
(3.1 cm2 compared with 0.78 cm2). Each drug administra-
tion was separated by a washout period of at least 72
hours.
A commercially available injectable fentanyl citrate product
(Fentanyl Citrate Injection, Hospira, Inc., Lake Forest, IL;
Lot 44-296-DK, Expiration August 1, 2008) was used for
the intravenous and oral doses. The buccal dosage form
contained fentanyl citrate, but the dosage is expressed as
fentanyl free base.
Prior to application of the buccal soluble ﬁlm doses, the
subjects rinsed their mouths with water. Buccal doses
were placed on the mucosa inside the cheek below the
level of the lower teeth. Each ﬁlm was then applied to the
mucosa and held in place for a few seconds until it was
moistened by saliva and adhered to the mucosal mem-
brane. The subjects were instructed not to rub the ﬁlm
with their tongue. With the four-ﬁlm regimen (D), two ﬁlms
were applied to the posterior portion and two to the ante-
rior portion of the contralateral sides of the mouth.
All of the subjects received oral naltrexone 50 mg approxi-
mately 12 hours and 1 hour prior to, and approximately 12
hours after study drug administration to block the respi-
ratory depressive effects of fentanyl in these opioid-naïve
subjects. Predose procedures were performed on the
evening of day 0 and the subjects received the study drug
1018
Vasisht et al.approximately 1 hour after consuming a standard light
breakfast on days 1, 4, 7, and 10. The subjects fasted for
4 hours after receipt of study medication.
Blood samples for measurement of fentanyl plasma con-
centrations were collected prior to drug administration (0
hour) and at 5, 10, 15, 20, 30, 45, and 60 minutes, and 2,
3, 4, 8, 12, 16, 20, 24, and 48 hours after each dose of the
study drug. Pharmacokinetic sampling times began with
the application of the ﬁrst ﬁlm when the subjects received
the four-ﬁlm regimen.
Sample Collection and Pharmacokinetic Analysis
Venous blood samples (7 mL) were collected in EDTA
Vacutainer® tubes (BD, Franklin Lakes, NJ). Within 30
minutes of collection, the samples were centrifuged and
the plasma fraction removed and stored at -20°C pending
analysis.
Fentanyl concentrations in plasma were determined by a
validated liquid chromatography with tandem mass
spectrometry method that has a lower limit of quantiﬁ-
cation of 0.0250 ng/mL and an upper limit of quantiﬁca-
tion of 5.00 ng/mL. Fentanyl-D5 was used as the internal
standard. Quantiﬁcation was performed by a weighted
(1/X2) linear least squares regression analysis that was
generated from calibration standards. Bioequivalence
between the 4 ¥ 200 mg and 1 ¥ 800 mg FBSF was
determined by comparison of the 90% conﬁdence inter-
vals (CIs) for the log-transformed exposure parameters
Cmax,A U C last, and AUCinf against the accepted 80% to
125% range.
The following pharmacokinetic parameters were calcu-
lated: Cﬁrst = ﬁrst measurable drug concentration in
plasma determined directly from individual concentration
time data; Cmax = maximum drug concentration in plasma
determined directly from individual concentration time
data; Tmax = t i m et oC max; lz = observed elimination rate
constant estimated by linear regression through at least
three points in the terminal phase of the log concentration
time proﬁle for each subject; t1/2 = observed terminal elimi-
nation half-life calculated as ln(2)/lz; AUC0–48 = area under
the drug concentration time curve from time 0–48 hours
calculated using the linear trapezoidal rule and extrapo-
lated using lz if measurable plasma concentrations were
not obtained throughout the 48-hour sampling period;
AUClast = area under the drug concentration time curve
calculated using linear trapezoidal summation from time
zero to the time of the last measurable concentration;
AUCinf = area under the drug concentration time curve
from time zero extrapolated to inﬁnity calculated as
AUClast + Clast/lz.
The absolute bioavailability of fentanyl was determined
using the following equation:
F
Dose AUC
Dose AUC
Dose iv iv
extravascular extravascular
iv =
()
()
=
∗ A AUC
Dose AUC
extravascular
extravascular iv ∗
Doseextravascular and AUCextravascular are those that pertain to
oral or buccal administration. Mean AUCinf was used in
these calculations. The percentage of the dose absorbed
through the buccal mucosa was estimated by subtracting
the AUCinf after oral administration from that after buccal
administration, dividing by the AUCinf after buccal admin-
istration, and multiplying by 100.
Safety Assessments
Safety monitoring was composed of physical examination,
vital signs, 12-lead electrocardiogram, laboratory studies,
and evaluation of subjects for adverse events and moni-
toring of oxyhemoglobin with a pulse oximeter.
Statistics
Plasma concentration time data were analyzed by non-
compartmental methods using WinNonlin® (Pharsight
Corporation, Mountain View, CA). Pharmacokinetic calcu-
lations were based on actual sampling times. The statis-
tical analysis was performed using SAS version 8.2 (SAS
Institute Inc., Cary, NC).
Plasma fentanyl concentrations that were below the limit
of quantiﬁcation after drug administration were assigned a
value of zero if collected prior to Cmax and were treated as
missing values if collected after Cmax. For the subjects with
measurable concentrations in predose samples, the ﬁrst
measurable concentration above the predose level after
drug administration was redeﬁned as the ﬁrst measurable
concentration.
The sample size chosen for this study was based on
conventional pharmacokinetic study designs, not a formal
power calculation.
Natural log-transformed values for Cmax,A U C last, and
AUCinf were analyzed for differences between treatments
and gender using an analysis of variance (ANOVA) model
and Schuirmann’s two one-sided t-test procedures at the
5% signiﬁcance level, analogous to the analysis used for
bioequivalence assessments; the ratio of the geometric
means and the 90% CIs were reported [10].
Values for Tmax after administration of a single 800 mg
buccal ﬁlm or four individual 200 mg ﬁlms were compared
with the Wilcoxon signed-rank test with a signiﬁcant dif-
ference deﬁned as P < 0.05.
Results
A total of 12 subjects were enrolled, each of whom com-
pleted all four treatment periods. A summary of the demo-
graphic characteristics of the participants in the study is
contained in Table 1. The mean age of the subjects was
27 years, 50% were men, and 50% were black. Measur-
able plasma concentrations of fentanyl were detected in
predose (0 hour) samples collected for some of the sub-
jects during periods 2, 3, and 4. The concentration of
fentanyl in all such samples was <5% of the Cmax for the
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included in the analysis without adjustment.
Single-Dose Pharmacokinetics
The plasma concentration time proﬁle of fentanyl admin-
istered by the intravenous, oral, and buccal routes is illus-
trated in Figure 1. The proﬁles for the two buccal
treatments overlap very closely and are distinct from those
for oral and intravenous administration.
Pharmacokinetic parameters for fentanyl in each of the
treatment periods are presented in Table 2. The mean Cmax
of fentanyl was identical (1.33 ng/mL), and exposure as
measured by mean AUCinf, was nearly identical (13.03 vs
13.09 hours/ng/mL) after administration of the two buccal
treatments (Table 2). Following the buccal doses, mean
Cmax and AUCinf were 1.9 and 2.0 times that of oral admin-
istration. The absolute bioavailability of fentanyl from the
buccal soluble ﬁlm treatments was 71%, which is approxi-
mately double that after oral administration (35%). The
percentage of an administered dose absorbed through
the buccal mucosa was calculated to be 51%.
Pharmacokinetic parameters were generally similar in the
males and the females after administration of a single
800 mg buccal dose of fentanyl (Table 3). The exception
was the mean t1/2, which was longer in the females (15.6
hours) than in the males (10.9 hours), a ﬁnding that may be
attributable to particularly long half-lives in two individuals.
When analyzed by ANOVA, the female : male ratios of the
geometric mean values for Cmax, AUClast, and AUCinf were
94.46%, 93.89%, and 102.5%, respectively. Due to the
small sample size (i.e., six female and six male subjects),
the power associated with these comparisons is low
(0.44, 0.34, and 0.34, respectively).
There were no differences in bioavailability in terms of
either the rate or extent of absorption of fentanyl after
administration by the buccal route as a single 800 mg ﬁlm
or as four 200 mg ﬁlms (Table 4). The median Tmax
occurred later after administration of fentanyl as four
200 mg ﬁlms compared with a single 800 mg ﬁlm (2.5 vs
1.5 hours, respectively), although the difference was not
statistically signiﬁcant (P = 0.0781 by Wilcoxon signed-
rank test).
Table 1 Demographic characteristics
Number of volunteers 12
Male : female gender 6:6
Mean age in years  SD (range) 27  6 (19–37)
Race, n (%)
Black 6 (50)
Caucasian 4 (33)
Hispanic or Latino 2 (17)
Mean height in cm  SD (range) 169.0  9.0
(154.5–180.5)
Mean weight in kg  SD (range) 70.7  6.4
(63.0–84.1)
SD = standard deviation.
Figure 1 Mean plasma con-
centration proﬁle. IV = intrave-
nous; SD = standard deviation.
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No serious adverse events were reported during the
study and no subject withdrew from treatment because
of adverse events. A total of nine adverse events were
reported by three subjects. All adverse events were con-
sidered to be mild in intensity and all were resolved
spontaneously. Contact dermatitis and menstrual
cramps were reported after intravenous administration
(N = 1 each); loose stool, nausea, and skin rash were
reported after oral administration (N = 1 each); dizziness
and headache were reported after buccal administration
of a single 800 mg buccal ﬁlm (N = 1 each), and consti-
pation and headache were reported after administration
of four 200 mg buccal ﬁlms (N = 1 each). No clinically
signiﬁcant observations or changes in vital signs, physi-
cal examinations, electrocardiograms, or clinical labora-
tory tests were identiﬁed in the subject population during
the study.
Discussion
Based on AUCinf estimates, this study showed that the
bioavailability of FBSF was 71%, which was greater than
the bioavailability after oral fentanyl (approximately 35%).
As determined by pharmacokinetic calculation, the per-
centage of the fentanyl dose absorbed through the buccal
mucosa was estimated to be 51%. Overall systemic expo-
sure as assessed by AUC and Cmax was nearly identical
after administration of 1 ¥ 800 mg and 4 ¥ 200 mg FBSF.
No differences in bioavailability were observed in the rate
and extent of absorption between 1 ¥ 800 mg and
4 ¥ 200 mg dosages, indicating that multiple small dose
units can be used interchangeably with higher dose units.
Furthermore, the pharmacokinetic proﬁle of FBSF was not
gender-dependent, with similar values for both males and
females for the exposure parameters of Cmax,A U C last, and
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Table 3 Statistical analysis of fentanyl plasma
pharmacokinetic parameters in female and male
subjects after administration of a single 800 mg
fentanyl buccal soluble ﬁlm
Parameter
Geometric LSM*
Ratio of LSM for
Female/Male, % Female Male
ln Cmax 1.265 1.337 94.46
ln AUClast 10.693 11.389 93.89
ln AUCinf 12.738 12.483 102.05
* Values are the least squares means (LSMs). LSMs are the
average of means associated with a treatment.
AUCinf = area under the drug concentration time curve from
time zero extrapolated to inﬁnity; AUClast = area under the drug
concentration time curve from time zero to the time of the last
measurable concentration; Cmax = maximum observed plasma
drug concentration.
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trointestinal and central nervous system disorders that
were mild in intensity and resolved spontaneously.
The safety results we report here are similar to that of other
formulations of fentanyl [11]. The lack of gender effects
reported here is different from the results previously
reported for the fentanyl buccal tablet, which reported a
20% to 30% increased systemic exposure for females [4].
In a comparative crossover study conducted in 26 volun-
teers, the following absolute bioavailability ratios were
reported: FBT, 65%; OTFC, 47%; and FBT administered
orally, 31% [11]. Although the bioavailability reported here
for FBSF (71%) is higher than that reported for FBT (65%),
the clinical relevance of this cross-comparison is not
known. The buccal absorption rate of 51% reported here
is comparable with the 48% transmucosal absorption for
FBT and more than two-fold higher than the 22% trans-
mucosal absorption reported for OTFC [11].
FBSF as examined in this study has distinct pharmacoki-
netic properties in comparison with other commercially
available fentanyl dosage forms intended for buccal
administration. The study demonstrates that a buccal
soluble ﬁlm dosage form delivers fentanyl with high abso-
lute bioavailability (71%) when administered as a single
800 mg ﬁlm or as four individual 200 mg ﬁlms and that the
two study treatments are bioequivalent.
The high fentanyl bioavailability produced by FBSF results
from the signiﬁcant drug fraction that undergoes transmu-
cosal absorption and therefore that escapes from ﬁrst-
pass metabolism. The effectiveness of transmucosal
absorption, in turn, likely reﬂects the effectiveness of the
ﬁlm inactive layer in minimizing the amount of fentanyl that
is swallowed with the saliva.
The observed bioequivalence when the same dose is
administered as a single ﬁlm or four different ﬁlms results
from the fact that the absorption produced by buccal ﬁlm
technology is proportional to the surface area of the ﬁlm.
Consequently, the absorption surface area with a single
800 mg ﬁlm is exactly the same as with four individual
200 mg ﬁlms.
The major limitation of the study is that it was conducted
in healthy volunteers, who had to be given naltrexone to
prevent respiratory depression. There may be differences
in the pharmacokinetics of fentanyl as experienced by the
patients with cancer, who may be undergoing chemo-
therapy or may be taking multiple concurrent medications.
However, because the dose is set individually by titration,
any such differences are not likely to be clinically relevant.
Another limitation is that the washout time was at least 72
hours, which corresponds to 3.8 terminal half-lives.
However, the residual concentration was <5% and was
taken into account in the calculations.
In conclusion, the absolute bioavailability of fentanyl from
the buccal soluble ﬁlm is determined in the present study
to be 71%. The direct relationship between the surface
area of the ﬁlm and the dose of fentanyl results in
bioequivalence between a single unit and that of multiple
dose units that give the same combined total dose. This
aspect provides conﬁdence in the titration of FBSF to an
effective dose for the management of breakthrough pain.
Acknowledgments
This study was funded by BioDelivery Sciences Interna-
tional, Inc. Editorial assistance was provided by Blair J.
Jarvis and Carol A. Lewis, PhD.
References
1 Caraceni A, Martini C, Zecca E, et al. Breakthrough
pain characteristics and syndromes in patients with
cancer pain. An international survey. Palliat Med
2004;18:177–83.
2 William L, Macleod R. Management of breakthrough
pain in patients with cancer. Drugs 2008;68:913–24.
Table 4 Exposure to fentanyl after administration of a single 800 mg fentanyl buccal soluble ﬁlm or four
200 mg fentanyl buccal soluble ﬁlms
Parameter
Geometric LSM*
Ratio of LSM for
4 ¥ 200 mg/800 mg, %;
90% CI ANOVA CV%
Four ¥ 200 mg
Films
Single 800 mg
Film
ln Cmax 1.269 1.301 97.50;90.50–105.04 9.83
ln AUClast 11.283 11.036 102.24;96.61–108.21 7.48
ln AUCinf 12.625 12.610 100.12;94.00–106.64 8.32
* Values are the least squares means (LSM).
ANOVA = analysis of variance; AUCinf = area under the drug concentration time curve from time zero extrapolated to inﬁnity;
AUClast = area under the drug concentration time curve from time zero to the time of the last measurable concentration;
CI = conﬁdence interval; Cmax = maximum observed plasma drug concentration; CV = coefficient of variation.
ANOVA CV% is the square root of the residual variance times 100.
1022
Vasisht et al.3 Portenoy RK, Payne D, Jacobsen P. Breakthrough
pain: Characteristics and impact in patients with
cancer pain. Pain 1999;81:129–34.
4 Zeppetella G, O’Doherty CA, Collins S. Prevalence
and characteristics of breakthrough pain in cancer
patients admitted to a hospice. J Pain Symptom
Manage 2000;20:87–92.
5 Zhang H, Zhang J, Streisand JB. Oral mucosal drug
delivery: Clinical pharmacokinetics and therapeutic
applications. Clin Pharmacokinet 2002;41:661–
80.
6 Streisand JB, Varvel JR, Stanski DR, et al. Absorption
and bioavailability of oral transmucosal fentanyl citrate.
Anesthesiology 1991;75:223–9.
7 Lee M, Kern SE, Kisicki JC, Egan TD. A pharmacoki-
netic study to compare two simultaneous 400
microg doses with a single 800 microg dose of oral
transmucosal fentanyl citrate. J Pain Symptom
Manage 2003;26:743–7.
8 Darwish M, Tempero K, Kirby M, Thompson J. Phar-
macokinetics and dose proportionality of fentanyl
effervescent buccal tablets in healthy volunteers. Clin
Pharmacokinet 2005;44:1279–86.
9 Darwish M, Kirby M, Robertson P Jr, Hellriegel E,
Jiang JG. Comparison of equivalent doses of fentanyl
buccal tablets and arteriovenous differences in fenta-
nyl pharmacokinetics. Clin Pharmacokinet 2006;45:
843–50.
10 Food and Drug Administration. Guidance for Industry:
Statistical Approaches to Establishing Bioequivalence.
Rockville, MD: Center for Drug Evaluation and
Research; 2001.
11 Darwish M, Kirby M, Robertson P Jr, Tracewell W,
Jiang JG. Absolute and relative bioavailability of fenta-
nyl buccal tablet and oral transmucosal fentanyl
citrate. J Clin Pharmacol 2007;47:343–50.
1023
Pharmacokinetics of Fentanyl Buccal Soluble Film